• In February 2026, MoonLake Immunotherapeutics reported full-year 2025 results showing a net loss of US$227.32 million, compared with US$118.94 million in 2024, and a basic loss per share from continuing operations of US$3.53 versus US$1.89.
• The widening loss underscores how the company’s spending and financial profile evolved over the year, sharpening investor focus on its path toward more sustainable economics.
• With the company’s recent share price gains, we’ll examine how the sharply higher annual net loss shapes MoonLake’s broader investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

What Is MoonLake Immunotherapeutics' Investment Narrative?

To own MoonLake Immunotherapeutics, you really have to believe that its SLK franchise in hidradenitis suppurativa and related inflammatory indications will eventually justify years of heavy cash burn, despite zero current revenue and no near term path to profitability. The February 2026 results, with the net loss rising to US$227.32 million, do not change the core short term catalysts: regulatory progress on the planned HS BLA in the second half of 2026 and readouts from ongoing SLK trials. What they do is sharpen the financial risk side of the story, especially after a year of share price gains and another step up in losses. With the Hercules debt facility and repeated equity raises already in place, this larger loss keeps funding needs and potential dilution firmly in focus.

However, there is one funding-related risk here that shareholders should not overlook.
Our valuation report here indicates MoonLake Immunotherapeutics may be overvalued.

Exploring Other Perspectives

The Simply Wall St Community currently contributes 1 fair value view clustered around US$23.86 per share, highlighting how even a single perspective can differ from the recent share price. Set that against MoonLake’s widening losses and reliance on external funding, and it becomes clear why it helps to weigh several viewpoints before forming a view on how this story might play out.

Explore another fair value estimate on MoonLake Immunotherapeutics - why the stock might be worth as much as 30% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your MoonLake Immunotherapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free MoonLake Immunotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MoonLake Immunotherapeutics' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.